Evidence that IgE is involved in immediate-type drug allergies is supported by the observation that the off-label use of anti-IgE antibody, omalizumab, effectively prevents such reactions during drug desensitization protocols [68, 69]. The gene discussed is IGHE; the disease is allergic disease.